12:10:21 EST Tue 29 Nov 2022
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:BLTE from 2021-11-30 to 2022-11-29 - 13 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2022-11-18 08:00U:BLTENews ReleaseBelite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)
2022-10-20 08:00U:BLTENews ReleaseBelite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data
2022-10-01 19:04U:BLTENews ReleaseBelite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022
2022-09-23 08:00U:BLTENews ReleaseBelite Bio Announces Late-Breaking Presentation at the American Academy of Ophthalmology 2022 Annual Meeting
2022-09-16 08:01U:BLTENews ReleaseBelite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China
2022-08-22 08:00U:BLTENews ReleaseBelite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008 in Stargardt Disease in the U.S.
2022-08-10 21:51U:BLTENews ReleaseBelite Bio Reports First Half 2022 Operational Highlights and Financial Results
2022-08-01 16:10U:BLTENews ReleaseBelite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results
2022-07-19 16:06U:BLTENews ReleaseBelite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease
2022-05-12 16:30U:BLTENews ReleaseBelite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
2022-05-05 08:00U:BLTENews ReleaseBelite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022
2022-05-03 16:30U:BLTENews ReleaseBelite Bio Announces Closing of $36 Million Initial Public Offering
2022-05-03 06:50U:BLTENews ReleaseBelite Bio Receives FDA Fast Track Designation For LBS-008